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Acute myocardial infarction in patients with end-stage renal [1]. Since the greatest increase in ESRD has occurred
disease. in older patients and those with diabetic renal failure,
Background. Ischemic heart disease is the major cause of there has been a progressive increase in the burden ofdeath in dialysis patients, with 22% of cardiac deaths attributed
cardiac disease in dialysis patients in the United Statesto acute myocardial infarction (AMI). Few data exist on sur-
and in the number of dialysis patients suffering acutevival of dialysis patients after AMI.
Methods. The United States Renal Data System (USRDS) myocardial infarction. In 1996 there were approximately
database of 627,983 patients was used to examine outcomes of 209,000 dialysis patients in the United States, with 14%
dialysis patients hospitalized from 1977 to 1995 for AMI. Long- receiving peritoneal dialysis and 85% hemodialysis (1%term survival was estimated by life-table method and indepen-
unknown) [2]. The total number of living ESRD patientsdent predictors of survival were examined in a comorbidity-
adjusted Cox model. In preliminary analyses we examined the in the United States was estimated to be 287,515 in 1996,
utilization of thrombolytic therapy for AMI in 1991 to 1995 and of whom 72.6% were receiving dialysis and 27.4% had
separately analyzed outcomes of dialysis patients hospitalized a functioning renal transplant [2].
1977 to 1994 at our own institution.
The burden of ischemic heart disease in ESRD pa-Results. There were 34,189 dialysis patients with AMI. The
tients has been independently confirmed by the Euro-in-hospital death was 26%. The all-cause mortality was 59%
at one year and 73% at two years. The one- and two-year pean Dialysis and Transplant Association (EDTA) Reg-
cardiac mortality was 41% and 52%, respectively. Patients with istry. In the United Kingdom the all-age death rate from
AMI 1990 to 1995 (vs. 1977 to 1984) had decreased mortality myocardial ischemia and myocardial infarction for pa-with RR (relative risk) 0.87 (0.83, 0.90). There were 16,063
tients commencing renal replacement therapy in 1985 topatients with AMI 1991 to 1995 receiving no reperfusion ther-
1990 was 16.6-fold greater in men and 17.7-fold greater inapy, and only 95 patients received intravenous thrombolytics,
of whom 16 received concurrent coronary revascularization. women, compared to the general population [3]. Similar
At our institution, the in-hospital death for 113 dialysis patients trends were found in Italy for increased risk of death
with AMI was 29% (52% mortality for transmural MI, 16% from ischemic heart disease with a 16.2-fold greater riskmortality for nontransmural MI).
in men and a 19.1-fold greater risk in women receivingConclusion. We conclude that dialysis patients with AMI
renal replacement therapy. Reflecting the underlying ge-suffer dismal long-term survival. Based on preliminary data,
thrombolytic therapy appears to be under-utilized in dialysis netic and environmental differences in susceptibility of
patients with AMI in the United States. selected populations to cardiovascular disease, the EDTA
registry has reported a striking geographic variation in
the death rate from myocardial ischemia and myocardial
Cardiovascular disease is the predominant cause of infarction in ESRD patients, with death rates five times
death in patients with end-stage renal disease (ESRD). greater in Northern European compared to Southern
In chronic hemodialysis patients approximately 44% of European women and four times greater in Northern
overall mortality is due to cardiac disease, with about European compared to Southern European men [3].
22% of these cardiac deaths attributed to acute myocar- A surprising paucity of published data has been avail-
dial infarction (AMI) [1]. The risk of cardiac and all- able on the survival of ESRD patients after AMI. Gun-
cause death is higher in older patients, those with diabetic narsson et al detailed the unfavorable outcome of 11
nephropathy, and patients receiving peritoneal dialysis patients with AMI (100% one year mortality) in a series
of 212 consecutive renal transplant recipients [4]. Janda
et al reported a more favorable survival (mean 30Key words: heart failure, ESRD, dialysis, kidney transplantation,
thrombolytic therapy. months) for 12 patients with AMI in a group of 355 renal
graft recipients [5]. 1999 by the International Society of Nephrology
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We have published data on the long-term survival of
ESRD patients in the United States after AMI [6]. Our
study was a retrospective analysis of 34,189 dialysis pa-
tients and 3,079 renal transplant patients hospitalized for
first (index) AMI occurring after the initiation of renal
replacement therapy from January 1977 to June 1995,
identified from the United States Renal Data System
(USRDS) database. Long-term survival for the end-
points of cardiac and all-cause death was estimated by
life table method [7]. The impact of demographics and
comorbid conditions was examined in a comorbidity-
adjusted Cox proportional hazards model [8] (utilizing
a previously developed comorbidity profiling methodol-
ogy) [9].
The dialysis group was 56% male and 44% female.
Eight percent of the patients were #44-years-old, 37%
were 45- to 64-years-old, 35% were 65- to 74-years-old,
and 20% were $75 years old. Seventy-one percent of
Fig. 1. Cumulative occurrence of acute myocardial infarction relatedpatients were white, 25% black, 1% Native American, to duration of end-stage renal disease. Symbols are: (d) dialysis patients,
2% Asian, and 1% other ethnic groups. Diabetes was N 5 34,189; (s) transplant patients, N 5 3,079.
the cause of renal failure in 34%, hypertension in 30%,
and other causes in 36%. The renal transplant patient
group was predominantly male (72%) and younger.
sion.” In 1990 to 1995 the all-cause mortality was 62%Thirty-four percent were #44-years-old, 55% were 45-
at one year and 74% at two years. The one and two yearto 64-years-old, 10% were 65- to 74-years-old and 1%
cardiac mortality in 1990 to 1995 was 42% and 52%,were $75-years-old. Eighty-four percent of the patients
respectively. The persistence of bad outcomes is onlywere white, 14% were black, and 2% were other ethnic
partially attributable to the increasing proportion ofgroups. Diabetes was the cause of renal failure in 31%,
older, diabetic patients. In a comorbidity-adjusted Coxhypertension in 14%, and other causes in 55%. The ma-
proportional hazards model there was a 13% reductionjority of myocardial infarctions were “recent,” as 60%
in risk [relative risk (RR) 0.87 (0.83, 0.90)] of all-causeof the dialysis patients and 64% of the transplant patients
death for 1990 to 1995 versus 1977 to 1984, a small im-sustained AMI in 1990 to 1995.
provement in AMI survival compared to modern treat-We examined the temporal pattern of acute myocar-
ment outcomes in the non-ESRD population. Renaldial infarction occurrence in relation to initiation of renal
transplant patients fared considerably better. The in-replacement therapy (Fig. 1). There appeared to be an
hospital death was 11.5%. Their one and two year all-early hazard of AMI related to dialysis initiation, as 29%
cause mortality was 24% and 30%, respectively. Theof infarcts occurred within one year and 52% within two
cardiac mortality was proportionally smaller, as the car-years of dialysis initiation. In renal transplant patients
diac mortality was only 10% at one year and 11% at15% of infarcts occurred within the first year after trans-
two years. Renal transplant patients with diabetic ne-plantation and 29% within two years. This comparison
phropathy had a cardiac mortality of 13% at one yearis confounded by the dissimilarity of these two groups,
and 15% at two years. In a preliminary analysis of 4,250but it suggests that dialysis may be a “stress test” for
renal transplant patients with AMI in 1977 to 1996, theoccult coronary artery disease (or perhaps a catalyst for
relative risk of all-cause death in a comorbidity-adjustedthe development of ischemic heart disease). Cardiac risk
Cox model was 0.56 (0.45, 0.68) for AMI in 1990 to 1996stratification of ESRD patients has conventionally been
versus 1977 to 1984 [abstract; Herzog et al, Circulationperformed in the context of renal transplant evaluation.
98(Suppl I):I-556, 1998]. We surmise that a significantWe would argue that a similar approach should be con-
degree of selection bias makes direct comparison of thesesidered for ESRD patients at dialysis initiation.
two ESRD groups problematic (the “sickest” ESRD pa-Figure 2 summarizes the dismal long-term survival of
tients are not deemed transplant-eligible). Nevertheless,dialysis patients suffering AMI in the United States. The
it is difficult to comprehend the dismal survival of dialysisin-hospital death was 26%. The one and two year all-
patients in the United States with AMI in the moderncause mortality were 59% and 73%, respectively. The
treatment era.one and two year cardiac mortality were 41% and 52%,
We have reported preliminary data suggesting a strik-respectively. Even more astounding (from a cardiolo-
gist’s perspective) is the mortality in the “era of reperfu- ing under-utilization of thrombolytic therapy in dialysis
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thy that no trials of thrombolytic therapy for AMI have
included dialysis patients, potentially making active
treatment decisions more difficult. Finally, minimal data
exist on the clinical presentation of AMI in dialysis pa-
tients, including potential eligibility (by ECG criteria)
for thrombolytic therapy.
Minimal data exist on the clinical characteristics of
dialysis patients with AMI [abstracts: Kong et al, Circula-
tion 88(Suppl I):I-49, 1993; Rubin et al, J Am Coll
Cardiol 29:67A, 1996]. In a preliminary communication,
Kong et al reported 33% in-hospital deaths in 45 dialysis
patients with AMI (80% non-Q-wave) versus 4% for
nonrenal control patients [abstract; Kong et al, Circula-
tion 88 (Suppl I):I-49, 1993]. Nine of these 45 patients had
unexpected ventricular fibrillation during hemodialysis,
with five lethal outcomes. Ifudu, Miles and Friedman
retrospectively identified 13 hemodialysis patients with
AMI and identified risk factors for intradialytic hypoten-
sion, but no patient suffered intradialytic death [10]. At
our own institution (Hennepin County Medical Center,
Fig. 2. Estimated mortality of dialysis patients after acute myocardial Minneapolis, MN USA), dialysis has been traditionally
infarction. Symbols are: (solid black line) all-cause mortality; (grey line)
deferred in the first 24 hours after AMI presentation,cardiac mortality. Bars are mortality 6 se (from Herzog CA, Ma JZ,
Collins AJ: Poor long-term survival after acute myocardial infarction unless forced by acute metabolic instability or circulatory
among patients on long-term dialysis. N Engl J Med 339:799–805, 1998; congestion.
used with permission).
We have performed a preliminary analysis of our own
institutional experience at Hennepin County Medical
Center from a retrospective chart review from the Re-
gional Kidney Disease Program (RKDP) of patients hos-patients with AMI in the United States [abstract; Herzog
et al, Circulation 96(Suppl I):I-202, 1997]. Using Medi- pitalized for AMI from 1977 to 1994. There were 113
patients (63 men, 50 women) who were 63 6 11 (rangecare Part A (institutional) and Part B (physician/sup-
plier) claims data in the USRDS database, we identified 30 to 85) years old. Nearly half (47%) had ESRD second-
ary to diabetes mellitus. Most patients (81%) received16,063 chronic dialysis patients hospitalized for first AMI
from January 1991 to June 1995 who did not receive hemodialysis. Of the 113 dialysis patient with AMI, non-
transmural MI was identified in 74 patients, transmuralcoronary reperfusion therapy. Only 95 patients received
thrombolytic therapy for coronary reperfusion, of whom MI in 31 patients (12 anterior, 18 inferior, and 1 lateral),
and unclassified (left bundle branch block) in 8 dialysis16 had concurrent PTCA. The two year survival for all-
cause death was 25% in patients not receiving thrombo- patients. The in-hospital mortality was 16% for the 74
patients with nontransmural MI, 52% for the 31 patientslytics and it was 43% for the 79 patients in the thrombo-
lytic-treated group. The two year cardiac survival was with transmural MI, and 29% for all 113 patients. Pa-
tients with anterior MI had a 50% in-hospital mortality47% in patients not receiving thrombolytics and 62%
in those 79 patients receiving only thrombolytics. In a and patients with acute inferior MI had a surprisingly
high 56% in-hospital mortality. Our data suggest thatcomorbidity-adjusted Cox model thrombolytic therapy
was associated with a 33% reduction in all-cause death roughly a third of dialysis patients with AMI might be
thrombolytic-eligible. The definitive serologic diagnosis[RR 5 0.67 (0.50, 0.89)]. Even allowing for potential
under-reporting in claims data, it would appear that dial- of myocardial necrosis in dialysis patients (particularly
for small infarcts) is problematic in series (includingysis patients with AMI in the United States are not re-
ceiving thrombolytic therapy, a conclusion supported by ours) relying on older enzymatic markers (such as, creati-
nine kinase) [11], but troponin I assays may offer higherthe poor survival in the untreated group of 16,063 pa-
tients and the improved survival in the small treatment diagnostic sensitivity and specificity [12].
The optimal therapeutic strategy for treatment of AMIgroup. This under-utilization of thrombolytic therapy
may potentially reflect the hesitancy of clinicians to use in dialysis patients is unknown, but a reasonable ap-
proach would be “direct” (immediate) PTCA if availablethrombolytic therapy in the presence of the relative con-
tra-indications of severe hypertension, recent arterial (given the hemorrhagic risk with thrombolysis) and
thrombolytic therapy if PTCA is not available, coupledpuncture (including fistulas), and “hemostatic abnormal-
ities” occurring in the dialysis population. It is notewor- with adjunctive aspirin, b-blocker, and ACE-inhibitor
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son G, Valderrabano F: Report on management of renal failuretherapy. Given the paucity of clinical data on AMI in
in Europe, XXII, 1991. Nephrol Dial Transplant (Suppl 2):7–35,
dialysis patients, we propose that a registry be estab- 1992
4. Gunnarsson R, Lofmark R, Nondlander R, Nyquist O, Grothlished for the prospective collection of data on AMI,
CG: Acute myocardial infarction in renal transplant recipients:particularly relating to eligibility for acute reperfusion incidence and prognosis. Eur Heart J 5:218–221, 1984
therapy, treatment, and clinical outcome. Dialysis pa- 5. Janda P, Stribrna J, Korandova V, Kocandrle V: Acute myocar-
dial infarction after renal transplantation. Cor Vasa 29:463–467,tients suffer high cardiac mortality and dismal long-term
1987survival after AMI. As a group at high cardiac risk they 6. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after
acute myocardial infarction among patients on long-term dialysis.also may potentially receive the most benefit from at-
N Engl J Med 339:799–805, 1998tempts at active intervention.
7. Kaplan EL, Meier P: Nonparametic estimation from incomplete
observations. J Am Stat Assoc 53:457–481, 1958
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